Calidi Biotherapeutics Inc (CLDI)
0.2304
-0.01
(-4.79%)
USD |
NYAM |
May 17, 16:00
0.2304
0.00 (0.00%)
After-Hours: 20:00
Calidi Biotherapeutics SG&A Expense (Quarterly): 5.862M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 5.862M |
| September 30, 2023 | 3.97M |
| December 31, 2022 | 2.425M |
| Date | Value |
|---|---|
| September 30, 2022 | 5.041M |
| December 31, 2021 | 1.945M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
1.945M
Minimum
Dec 2021
5.862M
Maximum
Dec 2023
3.849M
Average
3.97M
Median
Sep 2023
SG&A Expense (Quarterly) Benchmarks
| Minerva Neurosciences Inc | 2.515M |
| Viking Therapeutics Inc | 9.97M |
| CytomX Therapeutics Inc | 7.754M |
| Genprex Inc | 2.270M |
| Janux Therapeutics Inc | 7.343M |